Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Iprona Lana Ag/Spa currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity involves 1 distinct examiner and 1 distinct art unit. MI, QIUWEN is the busiest examiner for the portfolio, overseeing 1 pending action.
The concentration of the workload in 1 distinct art unit suggests a specialized focus within the Biotechnology & Pharmaceuticals sector. For practitioners, the prosecution is currently tied to the individual review of MI, QIUWEN. This centralization means that the outcome of the 1 pending office action will be determined by the specific interpretations of this examiner.
Monitoring the examiner's history and the specific requirements of the 1 distinct art unit will be essential for navigating the current prosecution landscape for the company. The resolution of this 1 action will provide significant insight into the company's standing within the patent office. Practitioners should prepare for a focused interaction with MI, QIUWEN to move the portfolio forward and understand the likely timeline for allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MI, QIUWEN | 1 | 68.4% | +49.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711600 | ELDERBERRY EXTRACT FOR USE IN A METHOD OF PREVENTING OR TREATING A SARS-CoV-2 INFECTION | MI, QIUWEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711600 | ELDERBERRY EXTRACT FOR USE IN A METHOD OF PREVENTING OR TREATING A SARS-CoV-2 INFECTION | MI, QIUWEN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711600 | ELDERBERRY EXTRACT FOR USE IN A METHOD OF PREVENTING OR TREATING A SARS-CoV-2 INFECTION | MI, QIUWEN | 1655 | §102§103§112 | Non-Final OA | — | Pending | May 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial